Zynerba Pharmaceuticals
Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions such as Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and...
EPIC: | ZYNE |
Market: | NASDAQ:ZYNE |
52-week High/Low: | $12.50 / $2.82 |
Sector: | Pharma & Biotech |
Market Cap: | $92.01M |
Website: | zynerba.com |
col 3
col 4
col 5
col 6